Share this article
Share this article
MADRID, Feb. 10, 2021 /PRNewswire/ MedLumics, a privately held medical device company developing AblaView®, the first optically-guided real-time ablation catheter system for the treatment of Atrial Fibrillation (AF), announced today that it has closed an upsized EUR 18 million (USD 21.7 million) financing round and has appointed Rich Ferrari as Chairman of the Board of Directors. MedLumics optical catheter displays lesion creation in real-time providing the physician with direct visual confirmation of conduction tissue denaturation.
Kurma Partners joined the round which includes and was initially led by Asabys Partners, along with new investors, VI Partners Swiss Innovation and CDTI Innvierte Economía, and existing investors Andera Partners, Caixa Capital Risc and Innogest Capital II. Having achieved pre-clinical feasibility in 2020, these proceeds will now enable MedLumics to initiate first in-human regulatory clinical studies and automa
MedLumics Proprietary Technology to be presented at 26th Annual International AF Symposium
- MedLumics is developing a unique real-time, optically-guided ablation catheter to improve treatment of Atrial Fibrillation by RadioFrequency Ablation and Pulsed Field Ablation
- Presentation on Direct Lesion Assessment using Photonics during AF Ablation
News provided by
Share this article
Share this article
MADRID, Jan. 28, 2021 /PRNewswire/ MedLumics, a privately held medical technology company developing AblaView®, an optically-guided RadioFrequency (RF) catheter ablation system for the treatment of Atrial Fibrillation (AF), announced today the first public communication on its technology using photonics during AF ablation at the upcoming 26
Renowned cardiologist Dr Atul Verma, FHRS, FRCPC, Director of Arrhythmia Services at Southlake Regional Health Care Centre in Newmarket, Ontario, Canada will present during